Medical University Innsbruck

i-med.ac.at

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

183

Active

50

Phase 3

7

Total enrollment

360,688

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Obinutuzumab1
Predniso(lo)ne1
neoadjuvant therapy with Pembrolizumab/Lenvatinib1
Adjuvant Treatment Phase1
Alfa1 Antitrypsin1
Blood sampling2
packed red blood cells1

Next readouts

  • 2021-03-01
  • 2023-12
  • 2025-07
  • 2028-06-30
  • 2028-09

Top conditions

  • COVID-196
  • Atherosclerosis4
  • Cardiovascular Diseases4
  • Covid193
  • Major Depressive Disorder3
  • Heart Failure3
  • Healthy3
  • Apnea2

Frequently asked questions about Medical University Innsbruck

How many clinical trials does Medical University Innsbruck have on ClinicalTrials.gov?
Medical University Innsbruck is listed as the lead sponsor on 183 clinical trials in ClinicalTrials.gov, 50 of which are currently active (recruiting, enrolling, or ongoing).
How many of Medical University Innsbruck's trials are in Phase 3?
7 of Medical University Innsbruck's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does Medical University Innsbruck focus on?
Medical University Innsbruck's most-studied conditions on ClinicalTrials.gov are COVID-19, Atherosclerosis, Cardiovascular Diseases, Covid19, Major Depressive Disorder.
When are Medical University Innsbruck's next clinical trial readouts?
Medical University Innsbruck has 5 upcoming primary-completion readouts tracked here; the soonest is “Connective Tissue Diseases and Lung Manifestations”, expected around 2021-03-01.